The melanoma trial is being conducted at New York University Medical Center, while the ovarian cancer vaccine trial is at the Roswell Park Cancer Institute in Buffalo, N.Y. The trials are assessing the safety and the anti-tumor immune response of the so-called NY-ESO-1 recombinant protein cancer vaccine alone and in combination with other agents, according to the Cancer Research Institute (CRI), an organization that has recently given $450,000 to Cornell to support vaccine production at the Bioproduction Facility. The facility is a partnership between the Ludwig Institute for Cancer Research and Cornell. The goal of these trials is to maximize the body's immune response to the NY-ESO-1 protein.NY-ESO-1 is an antigen found in normal testis and in various tumours. The peptide vaccine stimulates the immune system against cells expressing the NY-ESO-1 antigen leading to lysis of tumour cells (no word on how it affects 'normal testis'). The vaccine isn't meant to be preventative, but rather to stimulate the body's response against an existing tumour.
Wednesday, September 02, 2009
A clinical trial for a new treatment for ovarian cancer and melanoma is about to begin using a vaccine developed at Cornell University. From the press release: